- Home
- IGMS vs FHTX Comparison
IGMS vs FHTX Comparison
Compare IGMS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- FHTX
- Stock Information
- Founded
- IGMS 1993
- FHTX 2015
- Country
- IGMS United States
- FHTX United States
- Employees
- IGMS N/A
- FHTX N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- IGMS Health Care
- FHTX Health Care
- Exchange
- IGMS Nasdaq
- FHTX Nasdaq
- Market Cap
- IGMS 528.6M
- FHTX 513.7M
- IPO Year
- IGMS 2019
- FHTX 2020
- Fundamental
- Price
- IGMS $7.48
- FHTX $5.51
- Analyst Decision
- IGMS Buy
- FHTX Strong Buy
- Analyst Count
- IGMS 8
- FHTX 5
- Target Price
- IGMS $16.25
- FHTX $13.80
- AVG Volume (30 Days)
- IGMS 213.0K
- FHTX 155.9K
- Earning Date
- IGMS 11-08-2024
- FHTX 11-04-2024
- Dividend Yield
- IGMS N/A
- FHTX N/A
- EPS Growth
- IGMS N/A
- FHTX N/A
- EPS
- IGMS N/A
- FHTX N/A
- Revenue
- IGMS $2,918,000.00
- FHTX $25,515,000.00
- Revenue This Year
- IGMS $386.95
- FHTX N/A
- Revenue Next Year
- IGMS N/A
- FHTX $11.54
- P/E Ratio
- IGMS N/A
- FHTX N/A
- Revenue Growth
- IGMS 57.64
- FHTX N/A
- 52 Week Low
- IGMS $6.17
- FHTX $2.70
- 52 Week High
- IGMS $22.50
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- IGMS 31.94
- FHTX 26.55
- Support Level
- IGMS $7.00
- FHTX $4.57
- Resistance Level
- IGMS $10.80
- FHTX $8.45
- Average True Range (ATR)
- IGMS 1.02
- FHTX 0.57
- MACD
- IGMS -0.10
- FHTX -0.18
- Stochastic Oscillator
- IGMS 10.39
- FHTX 24.26
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.